3 August 2026

Osteopore completes first Hainan custom orthopaedic implantation

Australian-Singaporean regenerative medicine company **Osteopore Limited** (**ASX: OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce that the first patient in Hainan has successfully received treatment of a bone defect in the upper arm with a custom Osteopore orthopaedic device.

The surgical team used the customised device to reconstruct a 12cm bone defect in the upper limb of a patient following the resection of a malignant tumour.

Under normal circumstances, the patient would have been treated with a permanent device. However, based on the clinical experience of the surgical team, such a device would only be functional for 5-10 years, and subsequent revision surgeries will be necessary.

Due to the patient's age (6 years old), a regenerative solution was a better solution as it has the potential to avoid multiple revision surgeries.

As announced on 26 May 2026[1], Osteopore received approval from the Hainan Medical Products Administration (Hainan FDA) for the clinical use and sale of its orthopaedic custom

[1] ASX announcement "OSX secures Hainan FDA approval for orthopaedic devices", 26 May 2026

medical devices at the Hainan branch hospital[2] of Shanghai Ruijin Hospital, a top-tier, 3A-ranked hospital[3] under the Shanghai Jiao Tong University School of Medicine, located within the Hainan Boao Lecheng International Medical Tourism Pilot Zone.

As outlined in the announcement dated 26 May 2026[1], the Hainan FDA approval is a license which enables the Company to sell and market its devices in the Boao Lecheng International Medical Tourism Pilot Zone, which is China's strategic and only special medical zone, benefiting from preferential national-level policies that allow innovative medical technologies and devices to be used clinically prior to receiving full mainland approval[4]. It allows companies to generate real-world data that can later support nationwide NMPA registration, making the Hainan FDA approval both an accelerated commercial launchpad and a powerful regulatory springboard toward full China-wide market access.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Dr Yujing Lim
Chief Executive Officer
Osteopore Limited
E: lim_yujing@osteopore.com

Mark Leong
Executive Chairman
Osteopore Limited
E: mark_leong@osteopore.com

[2] https://www.boaolecheng.com/index/mechanism/article/id/6.html

[3] https://www.chinamed.cc/blog/china-hospital-grading-system

[4] https://en.hainan.gov.cn/englishsite/ici/202506/d209a720422d4ba9985120cebebf0eaf.shtml?ddtab=true

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.